| Maeli Contreras |
3 years ago |
Features |
- Cloud Optimized
- Small Molecule Drug Design
- Utilization of Artificial Intelligence and Machine Learning |
- Cloud Optimized
- Small Molecule Drug Design
- Powered by AI/ML |
| Maeli Contreras |
3 years ago |
Description |
NeuroX1 is a computational drug design company building a groundbreaking platform to better understand degenerative disorders affecting the brain. We harness the power of AI and machine learning in computational drug discovery to create the next generation of therapeutics for neurological conditions. |
NeuroX1 is a computational drug design company building a groundbreaking platform to better understand degenerative disorders affecting the brain. We harness the power of Artificial Intelligence (AI) and machine learning (ML) to create the next generation of therapeutics for neurological conditions. |
| Maeli Contreras |
3 years ago |
Description |
NeuroX1 is a computational drug design company building a groundbreaking platform to better understand degenerative disorders affecting the brain. We harness the power of AI and machine learning in computational drug discovery to develop the next generation of therapeutics for neurological conditions. |
NeuroX1 is a computational drug design company building a groundbreaking platform to better understand degenerative disorders affecting the brain. We harness the power of AI and machine learning in computational drug discovery to create the next generation of therapeutics for neurological conditions. |
| Maeli Contreras |
3 years ago |
Description |
NeuroX1 is a computational drug design company building a groundbreaking platform to better understand degenerative disorders affecting the brain. We leverage the capabilities of AI and machine learning in computational drug discovery to develop the next generation of therapeutics for neurological conditions. |
NeuroX1 is a computational drug design company building a groundbreaking platform to better understand degenerative disorders affecting the brain. We harness the power of AI and machine learning in computational drug discovery to develop the next generation of therapeutics for neurological conditions. |
| Maeli Contreras |
3 years ago |
Description |
NeuroX1 is a computational drug design company building a groundbreaking platform to better understand degenerative disorders affecting the brain. We leverage the capabilities of AI and machine learning in computational drug discovery to develop the next generation of therapeutics for neurological disorders. |
NeuroX1 is a computational drug design company building a groundbreaking platform to better understand degenerative disorders affecting the brain. We leverage the capabilities of AI and machine learning in computational drug discovery to develop the next generation of therapeutics for neurological conditions. |
| Maeli Contreras |
3 years ago |
Description |
NeuroX1 is a computational drug design company building an innovative platform to better understand degenerative disorders affecting the brain. We leverage the capabilities of AI and machine learning in computational drug discovery to develop the next generation of therapeutics for neurological disorders. |
NeuroX1 is a computational drug design company building a groundbreaking platform to better understand degenerative disorders affecting the brain. We leverage the capabilities of AI and machine learning in computational drug discovery to develop the next generation of therapeutics for neurological disorders. |
| Maeli Contreras |
3 years ago |
Description |
NeuroX1 is a computational drug design company building an innovative platform to deepen our understanding of degenerative disorders of the brain. We leverage the capabilities of AI and machine learning in computational drug discovery to develop the next generation of therapeutics for neurological disorders. |
NeuroX1 is a computational drug design company building an innovative platform to better understand degenerative disorders affecting the brain. We leverage the capabilities of AI and machine learning in computational drug discovery to develop the next generation of therapeutics for neurological disorders. |
| Maeli Contreras |
3 years ago |
Description |
NeuroX1 is a computational drug design company building an innovative platform to deepen our understanding of degenerative disorders affecting the brain. We leverage the capabilities of AI and machine learning in computational drug discovery to develop effective therapies for these types of disorders. |
NeuroX1 is a computational drug design company building an innovative platform to deepen our understanding of degenerative disorders of the brain. We leverage the capabilities of AI and machine learning in computational drug discovery to develop the next generation of therapeutics for neurological disorders. |
| Maeli Contreras |
3 years ago |
Description |
NeuroX1 is a computational drug design company building a platform to better understand degenerative disorders of the brain. making computational drug discoveries using AI/ML to create therapeutics for neurodegenerative disorders.
Currently, NeuroX1 is developing a target ID and drug discovery platform leveraging proprietary generative AI algorithms to create the next generation of therapeutics for neurological disorders. Our early-stage pipeline consists of several pre-clinical assets partnered with a variety of pharma companies and institutions. |
NeuroX1 is a computational drug design company building an innovative platform to deepen our understanding of degenerative disorders affecting the brain. We leverage the capabilities of AI and machine learning in computational drug discovery to develop effective therapies for these types of disorders. |
| Diego Ernesto Guevara Valencia |
3 years ago |
Why unique? |
|
We are pioneering AI-driven neurotherapeutics, accelerating discoveries in the field of brain disorders through computational biology. |
| Diego Ernesto Guevara Valencia |
3 years ago |
Problem Solving |
Accelerating the discovery of novel neurotherapeutics |
Accelerating the discovery of novel neurotherapeutics. |
| Diego Ernesto Guevara Valencia |
3 years ago |
Contact Phone |
512-270-3958 |
15122703958 |
| Diego Ernesto Guevara Valencia |
3 years ago |
AngelList |
|
neurox1 |
| Diego Ernesto Guevara Valencia |
3 years ago |
Description |
NeuroX1 is a computational drug design company building a platform to better understand degenerative disorders of the brain.
Computational drug discovery using AI/ML to create therapeutics for neurodegenerative disorders. |
NeuroX1 is a computational drug design company building a platform to better understand degenerative disorders of the brain. making computational drug discoveries using AI/ML to create therapeutics for neurodegenerative disorders.
Currently, NeuroX1 is developing a target ID and drug discovery platform leveraging proprietary generative AI algorithms to create the next generation of therapeutics for neurological disorders. Our early-stage pipeline consists of several pre-clinical assets partnered with a variety of pharma companies and institutions. |
| Diego Ernesto Guevara Valencia |
3 years ago |
Address |
|
Austin, Texas, United States |
| Diego Ernesto Guevara Valencia |
3 years ago |
Features |
|
- Cloud Optimized
- Small Molecule Drug Design
- Utilization of Artificial Intelligence and Machine Learning |
| Diego Ernesto Guevara Valencia |
3 years ago |
Technology built with |
|
Google Analytics, Google Font API, Open Graph, Unpkg, Google Hosted Libraries, Google Ads, Webflow, Swiper, core-js, jQuery, CookieHub |
| Diego Ernesto Guevara Valencia |
3 years ago |
Logo |
 |
 |
| Diego Ernesto Guevara Valencia |
3 years ago |
Screenshot |
|
 |
| Max Dordevic |
3 years ago |
Competitors |
|
- Valence
- Covalent Technologies
|
| Max Dordevic |
3 years ago |
Twitter |
|
neurox_1 |
| Max Dordevic |
3 years ago |
Benefits |
|
Increase the speed and specificity of drug discovery through the use of generative chemistry. |
| Max Dordevic |
3 years ago |
Problem Solving |
|
Accelerating the discovery of novel neurotherapeutics |
| Max Dordevic |
3 years ago |
Tags |
|
- Biotechnology
- Life Science
- Artificial Intelligence
- AI
- Drug
- Pharmaceutical
- Pharmaceuticals
|
| Max Dordevic |
3 years ago |
Contact Phone |
|
512-270-3958 |
| Max Dordevic |
3 years ago |
Contact E-mail |
|
[email protected] |
| Max Dordevic |
3 years ago |
Logo |
|
|
| Max Dordevic |
3 years ago |
Target Customer |
|
Pharmaceutical Companies |
| Max Dordevic |
3 years ago |
State |
|
Texas |
| Max Dordevic |
3 years ago |
Type |
|
Startup |
| Max Dordevic |
3 years ago |
Business Type |
|
B2B (Business to Business) |
| Max Dordevic |
3 years ago |
Business Model Type |
|
Licensing |
| Max Dordevic |
3 years ago |
Industry |
|
Pharmaceuticals & Biotechnology |
| Max Dordevic |
3 years ago |
State Status |
|
Private Beta |
| Max Dordevic |
3 years ago |
Employees Number |
|
6 - 10 |
| Max Dordevic |
3 years ago |
Name |
|
NeuroX1 |
| Max Dordevic |
3 years ago |
Legal Name |
|
NeuroX1 Inc. |
| Max Dordevic |
3 years ago |
Phrase |
|
The new standard in computational neuroscience |
| Max Dordevic |
3 years ago |
City |
|
Austin |
| Max Dordevic |
3 years ago |
Postal Code |
|
78705 |
| Max Dordevic |
3 years ago |
Country |
|
United States |
| Max Dordevic |
3 years ago |
Description |
|
NeuroX1 is a computational drug design company building a platform to better understand degenerative disorders of the brain.
Computational drug discovery using AI/ML to create therapeutics for neurodegenerative disorders. |
| Max Dordevic |
3 years ago |
Date Founded |
|
2021-11-18 |
| Max Dordevic |
3 years ago |
URL |
|
www.neurox1.com |
| Max Dordevic |
3 years ago |
LinkedIn |
|
neurox1 |
| Max Dordevic |
3 years ago |
CrunchBase |
|
neurox1/signals_and_news |
